LT3360580T - Genetinio gydymo būdas, naudojant aav-xbp1s/gfp virusą ir jo panaudojimas amiotrofinės šoninės sklerozės prevencijai ir gydymui - Google Patents

Genetinio gydymo būdas, naudojant aav-xbp1s/gfp virusą ir jo panaudojimas amiotrofinės šoninės sklerozės prevencijai ir gydymui

Info

Publication number
LT3360580T
LT3360580T LTEPPCT/CL2016/000056T LT16852956T LT3360580T LT 3360580 T LT3360580 T LT 3360580T LT 16852956 T LT16852956 T LT 16852956T LT 3360580 T LT3360580 T LT 3360580T
Authority
LT
Lithuania
Prior art keywords
treatment
amiotrophic
xbp1s
aav
prevention
Prior art date
Application number
LTEPPCT/CL2016/000056T
Other languages
English (en)
Inventor
Claudio Andrés HETZ FLORES
Vicente Spiro VALENZUELA PATERAKIS
Original Assignee
Universidad De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Chile filed Critical Universidad De Chile
Publication of LT3360580T publication Critical patent/LT3360580T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/CL2016/000056T 2015-10-09 2016-09-30 Genetinio gydymo būdas, naudojant aav-xbp1s/gfp virusą ir jo panaudojimas amiotrofinės šoninės sklerozės prevencijai ir gydymui LT3360580T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2015003024A CL2015003024A1 (es) 2015-10-09 2015-10-09 Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica.
PCT/CL2016/000056 WO2017059554A1 (es) 2015-10-09 2016-09-30 Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrófica

Publications (1)

Publication Number Publication Date
LT3360580T true LT3360580T (lt) 2022-05-10

Family

ID=56081079

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/CL2016/000056T LT3360580T (lt) 2015-10-09 2016-09-30 Genetinio gydymo būdas, naudojant aav-xbp1s/gfp virusą ir jo panaudojimas amiotrofinės šoninės sklerozės prevencijai ir gydymui

Country Status (14)

Country Link
US (1) US10512698B2 (lt)
EP (2) EP4035687B1 (lt)
AU (1) AU2016336063B2 (lt)
CL (1) CL2015003024A1 (lt)
CY (1) CY1125031T1 (lt)
DK (1) DK3360580T3 (lt)
ES (2) ES2907684T3 (lt)
HR (1) HRP20220199T1 (lt)
HU (1) HUE057861T2 (lt)
LT (1) LT3360580T (lt)
PL (1) PL3360580T3 (lt)
PT (1) PT3360580T (lt)
SI (2) SI3360580T1 (lt)
WO (1) WO2017059554A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2015003242A1 (es) 2015-11-04 2016-10-14 Univ Chile Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras.
US20220184175A1 (en) * 2019-02-01 2022-06-16 Universidad De Chile Treatment of aging or age-related disorders using xbp1
CN112143693B (zh) 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460621B (zh) 2006-06-07 2016-01-27 建新公司 肌萎缩性侧索硬化和其他脊髓失调症的基因治疗
DK2066791T3 (da) 2006-10-03 2012-10-15 Genzyme Corp Genterapi for amyotrofisk lateralsklerose og andre rygmarvssygdomme
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
CL2014003590A1 (es) * 2014-12-30 2015-07-10 Univ Chile Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.

Also Published As

Publication number Publication date
ES2907684T3 (es) 2022-04-26
EP3360580B1 (en) 2021-12-01
EP4035687B1 (en) 2025-04-16
EP3360580A4 (en) 2019-03-13
HRP20220199T1 (hr) 2022-04-29
EP4035687A1 (en) 2022-08-03
AU2016336063B2 (en) 2023-07-13
HUE057861T2 (hu) 2022-06-28
EP3360580A1 (en) 2018-08-15
CL2015003024A1 (es) 2016-05-13
DK3360580T3 (da) 2022-02-21
SI3360580T1 (sl) 2022-05-31
AU2016336063A1 (en) 2018-05-24
US10512698B2 (en) 2019-12-24
WO2017059554A1 (es) 2017-04-13
US20190030188A1 (en) 2019-01-31
PT3360580T (pt) 2022-02-24
PL3360580T3 (pl) 2022-05-23
CY1125031T1 (el) 2023-03-24
SI4035687T1 (sl) 2025-07-31
ES3031262T3 (en) 2025-07-07

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL246449B (en) Conjugated 6-heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis b virus infection
LT3872085T (lt) Viruso prototipo sekos ir jų panaudojimas
DK3400291T3 (da) Manipuleret virus
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
LT3262037T (lt) Naujas chinolino darinys, skirtas panaudoti virusinių infekcijų gydymui ir prevencijai
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
LT3261642T (lt) Chinolino dariniai, skirti naudoti virusinės infekcijos gydymui arba prevencijai
HUE045906T2 (hu) Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
IL255259B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
LT3137078T (lt) Virusinio hepatito delta infekcijos gydymas
EP3365005C0 (en) MOPEIA RECOMBINANT VIRUS AND VACCINE PLATFORM
IL246643B (en) Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome
SI4035687T1 (sl) Postopek za genetsko zdravljenje z uporabo virusa aav-xbp1s/gfp in njegova uporaba pri preprečevanju in zdravljenju amiotrofične lateralne skleroze
ZA201803649B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
GB201813175D0 (en) Virus use
TH1601001266A (th) วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TH1501006890A (th) อนุพันธ์ไพริโดนสำหรับการบำบัดการติดเชื้อไวรัสและโรคอื่นเพิ่มเติม
GB201600380D0 (en) Modified virus
TH1601002905A (th) วิธีการและองค์ประกอบสำหรับการดัดแปลงที่มีเป้าหมายของจีโนม